CJC-1295 Without DAC (Modified GRF 1-29)⁠

CJC-1295 Without DAC | Research-Grade GHRH Analogue

CJC-1295 Without DAC (also professionally designated as Modified GRF 1-29) is a synthetic, 29-amino acid polypeptide analogue of native Growth Hormone-Releasing Hormone (GHRH). By completely omitting the Drug Affinity Complex (DAC), this specific compound is engineered exclusively for acute, short-duration cellular signaling assays.

The native GHRH molecule is subject to near-instantaneous degradation in vivo due to enzymatic cleavage. To resolve this limitation in a laboratory setting, Modified GRF 1-29 features four precise amino acid substitutions (at positions 2, 8, 15, and 27). These modifications shield the molecule from rapid dipeptidyl peptidase-4 (DPP-4) inactivation, extending its experimental half-life to approximately 30 minutes. This allows investigators to accurately observe natural, physiological pulsatile pituitary signaling loops without hyper-physiological accumulation or receptor down-regulation.

Experimental Research Context & Mechanisms

In preclinical modeling, CJC-1295 Without DAC serves as a vital reagent for examining endocrine pathway interactions, specifically targeting:

• Somatotroph Receptor Agonism: Binds selectively to G-protein coupled GHRH receptors on anterior pituitary cells, inducing an immediate downstream accumulation of cyclic adenosine monophosphate (cAMP).
• Pulsatile Secretion Kinetics: Because it lacks the long-acting DAC modification, it mimics the natural physiological “pulses” of growth hormone, allowing researchers to study physiological hormone secretion curves without exhausting pituitary reserves.
• Synergistic GHRP Co-Administration: Frequently studied in vitro alongside Growth Hormone Releasing Peptides (GHRPs) like Ipamorelin or GHRP-6 to map simultaneous, dual-receptor binding cascades and calculate amplification synergy metrics.

Laboratory Storage & Handling Protocols

To ensure maximum stability and chemical longevity of the polypeptide monomer matrix during extended laboratory trials, adhere to the following handling guidelines:

• Lyophilized Storage: Unreconstituted vials should be stored inside a laboratory freezer at -20°C for long-term preservation. Desiccated state storage prevents rapid peptide degradation. Avoid frequent freeze-thaw cycles.
• Reconstitution Calibration: Before introducing a bacteriostatic solvent, allow the vacuum-sealed vial to sit until it reaches ambient room temperature. This step drastically minimizes thermal shock to the structural amino acid bonds.
• Post-Solvent Management: Once reconstituted, store the liquid solution at temperatures between 2°C and 6°C. Keep protected from direct sunlight or ambient UV light exposure. It is highly recommended to complete data collection models within 14 days of introducing liquid solvents.